Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Inclusion Criteria: * Written informed consent and any locally-required authorization will be obtained from the patient prior to performing any protocol-related procedures, including screening evaluations * Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up * Histologically or cytologically confirmed recurrent non-small cell lung cancer not amenable to curative intent therapy or stage IV NSCLC * Known KRAS mutation status by Clinical Laboratory Improvement Act (CLIA) certified test * Documented progression following at least one line of chemotherapy or immunotherapy for metastatic or recurrent disease, or progression within 6 months of receiving adjuvant chemotherapy or concurrent chemotherapy for early stage or locally advanced disease * Biopsy accessible disease and willingness to undergo tumor biopsy * Measurable disease by RECIST 1.1 * Total body weight \> 30 kg * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Ability to take pills by mouth * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Hemoglobin \>= 9.0 g/dL * Total bilirubin total bilirubin =\<1.5 x upper limit of normal (ULN) (higher is allowed if in the setting of known Gilbert's disease) * Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamate py…